Pfizer Inc. and Eli Lilly & Co. plan to resume a Phase 3 trial of pain treatment tanezumab after the U.S. Food and Drug Administration lifted a partial clinical hold placed on the program in 2012.
from WSJ.com: US Business http://ift.tt/1DOxveO
via IFTTT
from WSJ.com: US Business http://ift.tt/1DOxveO
via IFTTT
No comments:
Post a Comment